Biotechnology company RubrYc Therapeutics, Inc., founded in 2017, has developed a proprietary machine learning-driven solution for the discovery of best-in-class and first-in-class epitope ...

"The combination of the Monash team's epitope discovery by immunopeptidomics and protein chemistry, T cell immunology at the ...

The development of Epitope Binning-seq represents a major advancement in antibody drug discovery. By providing a rapid, comprehensive, and cost-effective method for evaluating antibody epitope ...

By performing the whole antibody-discovery process in vitro and bypassing animal immunization, YUMAB eliminates potential epitope restriction by the host immune response. The resulting ...